These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35371841)

  • 1. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
    Alsafwani DM; Alotaibi HN; Alzaid JA; Alghamdi A; Almakhaita HM
    Cureus; 2022 Mar; 14(3):e23554. PubMed ID: 35371841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
    Mahzari MM; Alanazy AM; Feroz Z; Almani KM; Alghamdi MA; Almadani AS; Alzahrani MK; Alibrahim AR; Badri M
    Medicine (Baltimore); 2024 Jul; 103(29):e39026. PubMed ID: 39029073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
    Alshehri A; AlFaris N; Al Qahtani AM; Shams M; Yahia M
    Clin Obes; 2023 Aug; 13(4):e12594. PubMed ID: 37194338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.
    Albaker W; Al Sheikh M; Albakr A; Alkhafaji D; Al Besher E; Al-Hariri M
    Int J Gen Med; 2021; 14():8643-8650. PubMed ID: 34849008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.
    Ghuman NK; Saadah LM; Al Najjar MS; Shaheen DY; Am SI; Al Ali MM
    Clin Med Insights Endocrinol Diabetes; 2015; 8():67-72. PubMed ID: 26441485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.
    Mezquita-Raya P; Reyes-Garcia R; Moreno-Perez O; Escalada-San Martin J; Ángel Rubio Herrera M; Lopez de la Torre Casares M
    Diabetes Ther; 2015 Jun; 6(2):173-85. PubMed ID: 26055216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mean glycosylated hemoglobin in children with type 1 diabetes at King Fahad Medical City, Riyadh, Saudi Arabia.
    Alsaheel AY; Alayed SI; Alotaibi YM; Alfahhad AA; Alothman OM; Alnefaie HF
    J Family Community Med; 2020; 27(3):163-167. PubMed ID: 33354146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Cardiovascular Risk Factors Among Patients With Diabetes Mellitus Type 2 at King Fahad University Hospital, Saudi Arabia.
    Jatoi NA; Elamin YA; Said AH; Al-Namer B; Al-Muallim FA; Al-Nemer FF; Al-Halal FM
    Cureus; 2022 Sep; 14(9):e29489. PubMed ID: 36299951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
    Inoue K; Maeda N; Fujishima Y; Fukuda S; Nagao H; Yamaoka M; Hirata A; Nishizawa H; Funahashi T; Shimomura I
    Diabetol Metab Syndr; 2014; 6(1):95. PubMed ID: 25237400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
    Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
    Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients.
    Zameer R; Kamin M; Raja U; Wahab MU; Ishtiaq O; Raashid K; Ahmed N; Rehman AU
    Cureus; 2020 Aug; 12(8):e9937. PubMed ID: 32864274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of liraglutide after three years of treatment.
    Ponzani P; Scardapane M; Nicolucci A; Rossi MC
    Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
    Ghosal S; Sinha B
    Clin Diabetes Endocrinol; 2018; 4():11. PubMed ID: 29760945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.